WEKO3
アイテム
{"_buckets": {"deposit": "d49cc363-2f9d-428f-ad45-76862af77087"}, "_deposit": {"created_by": 2, "id": "80", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "80"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00000080", "sets": ["11"]}, "author_link": ["394", "395", "398", "397", "393", "399", "396", "400"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-09-14", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageStart": "15033", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "Scientific Reports"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Liposomal amphotericin B (L-AMB) is a broad-spectrum antifungal drug that is used to treat fungal infections. However, clinical evidence of its use in patients with renal failure is limited. Here, we aimed to identify factors associated with acute kidney injury (AKI) in patients administered L-AMB. We retrospectively utilized a combination of Diagnosis Procedure Combination data and laboratory data obtained from hospitals throughout Japan between April 2008 and January 2018. In total, 507 patients administered L-AMB were identified. After L-AMB treatment initiation, AKI, which was defined as a???1.5-fold increase within 7 days or???0.3 mg/dL increase within 2 days in serum creatinine according to the KDIGO criteria, was recognized in 37% of the total patients (189/507). The stages of AKI were stage 1 in 20%, stage 2 in 11%, and stage 3 in 7%. Five factors were associated with AKI of all stages: prior treatment with angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers or carbapenem; concomitant administration of catecholamines or immunosuppressants; and???3.52 mg/kg/day of L-AMB dosing. Serum potassium?\u003c?3.5 mEq/L before L-AMB therapy was associated with severe AKI of stage 2 and 3. Altogether, these factors should be carefully considered to reduce the occurrence of AKI in patients administered L-AMB.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Scientific Reports, 10(1), art.no.15033; 2020", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Nature"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1038/s41598-020-72135-y", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2020, The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article\u0027s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article\u0027s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/."}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "20452322", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takazono, Takahiro"}], "nameIdentifiers": [{"nameIdentifier": "393", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tashiro, Masato"}], "nameIdentifiers": [{"nameIdentifier": "394", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ota, Yuki"}], "nameIdentifiers": [{"nameIdentifier": "395", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Obata, Yoko"}], "nameIdentifiers": [{"nameIdentifier": "396", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakamura, Tomotaro"}], "nameIdentifiers": [{"nameIdentifier": "397", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Taiga"}], "nameIdentifiers": [{"nameIdentifier": "398", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishino, Tomoya"}], "nameIdentifiers": [{"nameIdentifier": "399", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Izumikawa, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "400", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "SciRep10_15033.pdf", "filesize": [{"value": "1.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1100000.0, "url": {"label": "SciRep10_15033.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/80/files/SciRep10_15033.pdf"}, "version_id": "bb79888f-d83a-44d0-8084-410d67464c02"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/40307", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-10-05"}, "publish_date": "2020-10-05", "publish_status": "0", "recid": "80", "relation": {}, "relation_version_is_last": true, "title": ["Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan"], "weko_shared_id": -1}
Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan
http://hdl.handle.net/10069/40307
http://hdl.handle.net/10069/40307d5f08a2f-0ab3-4f95-9024-4e1af33010e7
名前 / ファイル | ライセンス | アクション |
---|---|---|
SciRep10_15033.pdf (1.1 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-10-05 | |||||
タイトル | ||||||
タイトル | Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Takazono, Takahiro
× Takazono, Takahiro× Tashiro, Masato× Ota, Yuki× Obata, Yoko× Wakamura, Tomotaro× Miyazaki, Taiga× Nishino, Tomoya× Izumikawa, Koichi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Liposomal amphotericin B (L-AMB) is a broad-spectrum antifungal drug that is used to treat fungal infections. However, clinical evidence of its use in patients with renal failure is limited. Here, we aimed to identify factors associated with acute kidney injury (AKI) in patients administered L-AMB. We retrospectively utilized a combination of Diagnosis Procedure Combination data and laboratory data obtained from hospitals throughout Japan between April 2008 and January 2018. In total, 507 patients administered L-AMB were identified. After L-AMB treatment initiation, AKI, which was defined as a???1.5-fold increase within 7 days or???0.3 mg/dL increase within 2 days in serum creatinine according to the KDIGO criteria, was recognized in 37% of the total patients (189/507). The stages of AKI were stage 1 in 20%, stage 2 in 11%, and stage 3 in 7%. Five factors were associated with AKI of all stages: prior treatment with angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers or carbapenem; concomitant administration of catecholamines or immunosuppressants; and???3.52 mg/kg/day of L-AMB dosing. Serum potassium?<?3.5 mEq/L before L-AMB therapy was associated with severe AKI of stage 2 and 3. Altogether, these factors should be carefully considered to reduce the occurrence of AKI in patients administered L-AMB. | |||||
書誌情報 |
Scientific Reports 巻 10, 号 1, p. 15033, 発行日 2020-09-14 |
|||||
出版者 | ||||||
出版者 | Springer Nature | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 20452322 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1038/s41598-020-72135-y | |||||
権利 | ||||||
権利情報 | c 2020, The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Scientific Reports, 10(1), art.no.15033; 2020 |